Oral drug combo aims for deep remission in rare blood cancer
NCT ID NCT04463953
Summary
This study tested a combination of three oral drugs—zanubrutinib, ixazomib, and dexamethasone—for people newly diagnosed with symptomatic Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to two years and then stopped to see if the response lasted. Researchers hoped this time-limited approach would lead to deep remission and reduce the need for lifelong therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.